BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May 10, 2023.
May 10, 2023 schedule:
4:05 p.m. ET – 2023 first quarter financial results press release will be distributed.
Prior to the call - To participate in the teleconference, go to the following link to register and the teleconference number and a pin number for the teleconference will be sent to you:
https://register.vevent.com/register/BI1408073fde3e47ab889cfdc791e65ccf
5:00 p.m. ET - Conference call and simultaneous webcast begins.
The conference call will also be available via webcast, and may be accessed on the investor relations page of OraSure’s website, www.orasure.com. Please click on the webcast link and follow the prompts for registration and access, 10 minutes prior to the call.
If you are unable to participate, the webcast will be archived on OraSure’s website shortly after the call has ended and will be available for 14 days.
| Investor Contact: | Media Contact: |
| Scott Gleason | Amy Koch |
| SVP Investor Relations & Corp. Communications | Director Corporate Communications |
| 484-425-0588 | 484-523-1815 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.64 |
| Daily Change: | -0.15 -3.96 |
| Daily Volume: | 2,095,289 |
| Market Cap: | US$271.510M |
December 19, 2024 November 06, 2024 August 06, 2024 February 27, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
